REGULATORY

Japan’s First Humalog Biosimilar to Join NHI Price List on May 27

May 26, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s first biosimilar for Eli Lilly’s ultra-fast acting insulin Humalog (insulin lispro) will join the NHI price list on May 27 with a batch of other products that also includes a new Eylea (aflibercept) kit, the government’s official gazette revealed…

To read the full story

Sanofi Launches Japan’s 1st Humalog Biosimilar
June 30, 2020

REGULATORY

Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
GSK’s Exdensur, Lilly’s Inluriyo Missing from March Listing Roster
March 12, 2026
Truqap Price Cut Set at 10.7% from June under CEA Scheme
March 12, 2026
Avelox Gains Coverage for MDR-TB via Public Knowledge Filing
March 12, 2026
Council Floats 9.6% Growth Target for Japan’s On-Patent Drug Market
March 11, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…